Market View

U.S. Market
The U.S. market has shifted back to a Confirmed Uptrend. The status change was made after Thursday’s close
as both indices regained their respective 50-DMA, a multitude of quality growth ideas turned actionable, and
distribution was avoided for seven straight sessions ahead of a period where multiple days will begin to expire.
On Friday, indices pulled back to their respective 50-DMA, though little damage was done to leading stocks
given sizable gains earlier in the week. The S&P 500 added an eighth distribution day, though four will expire
over the next eight sessions. The Nasdaq’s count went unchanged at five total, with two set to expire over that
same time frame.

PerkinElmer

Key points from this report:

 

  • Buy PerkinElmer (PKI). The stock is actionable after breaking out from a seven-week flat base in heavy volume. Add to positions.
  • PerkinElmer has a top three market position in 65–70% of its product lines. Driven by increasing diagnostic revenue, recurring revenue now accounts for 75% of total revenue, up from 55% in 2014.
  • The company is now the global leader in biochemical prenatal testing, newborn screening, and global autoimmune in vitro diagnostics. Through this improving product mix as well as geographic expansion, the company has tripled its TAM to ~$50B.

Market View

U.S. Market
The U.S. market remains in an Uptrend Under Pressure. The S&P 500 and Nasdaq closed the week on a strong
note, rallying sharply off price support and now set to face resistance at their respective 50-DMA (S&P 500:

3,351; Nasdaq: 11,025). Distribution remains elevated at seven and six days, respectively, with one day expir-
ing on the Nasdaq next Wednesday.

Market View

The U.S. market remains in an Uptrend Under Pressure. The S&P 500 and Nasdaq are both now trading slightly
below their respective 50-DMA with six distribution days each. One distribution day will expire on the Nasdaq
next Wednesday. The S&P 500 is trading ~7% off highs with the next level of support at ~3,233, while the
Nasdaq is trading ~11% off highs with near-term support at ~10,700 before ~10,200. Both indices are being
dragged lower by big-cap tech as the majority of other leading ideas continue to base constructively.

Biocon

Key points from this report:

 

  • Buy Biocon. Buy as the stock is forming the right side of a cup base with a pivot at INR 446.95. Recent momentum is driven by the launch of Semglee (insulin glargine injection) with its partner Mylan (MYL). Management targets $1B in biosimilar revenue by FY22 from $270M in FY20, with expected earnings growth of 30% through FY22.
  • Strong pipeline. Biocon is the first company from India to have three FDA-approved biosimilars. The company has a rich pipeline of 28 biosimilar products, of which 11 are co-developed with Mylan. As of December 2019, Biocon biosimilars reached 1.29M patients, and the company aims to reach 5M patients by FY22.
  • Recent news. Equillium (EQ) has completed a pre-IND meeting with the FDA for the clinical development plans for itolizumab for the potential treatment of hospitalized COVID-19 patients. A phase 3 study is expected to begin in Q4. Itolizumab is an in-licensed drug from Biocon.
  • Looking forward. The company will announce Q2 FY20 results in October. For FY20 and FY21, consensus expects EPS growth of 50% and 43%, y/y, respectively

Market View

The U.S. market remains in an Uptrend Under Pressure. The S&P 500 and Nasdaq pulled back toward their re-
spective 50-DMA this week, with the S&P 500 sitting just above that level and the Nasdaq just below. Distribution

stands at five and six days, respectively, with one day set to expire on the S&P 500 and two on the Nasdaq next
week.

Transportation and Basic Material were the only two positive sectors this week, each rising ~1%. Retail, Technol-
ogy, and Energy declined the most, falling ~3–5%. Utility and Energy remain the only two sectors trading below

both their respective 50- and 200-DMA, though Health Care is also trading just below its 50-DMA. Industry
groups holding up best over the last week include Home Furnishings, Household Appliances, Home Builders,
Leisure, Apparel, Rails, and Miners. 54% of S&P 500 stocks are trading above their respective 50-DMA and 57%
are trading above their respective 200-DMA, compared with 71% and 62%, respectively, last week.

Market View

U.S. Market
The U.S. market has been moved to an Uptrend Under Pressure. The Nasdaq reversed sharply off its upper
channel line Thursday and broke below its 21-DMA Friday. Though the index did find strong support at its 50-
DMA, we believe this sharp break lower will lead to choppy action over the next several days to weeks. The index
avoided distribution on Friday, though the count did increase to six this week. The S&P 500 also sold off sharply
but managed to close at its 21-DMA Friday and avoid distribution as selling pressure was more severe across

mega-cap tech leaders, which pulled back into their respective bases. We will be looking for indices to hold sup-
port at their respective 50-DMA (S&P 500: 3,299; Nasdaq: 10,858) next week.